Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
ZHAOKE OPHTHALMOLOGY Aktie jetzt für 0€ handeln | |||||
12.06. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FOR TAB014 FOR THE TREATMENT OF WAMD | 1 | HKEx | ||
04.06. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - FDA CLEARANCE OF IND APPLICATION FOR CSA OPHTHALMIC GEL | 3 | HKEx | ||
19.05. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF NEW DRUG APPLICATION FOR CSA OPHTHALMIC GEL | - | HKEx | ||
16.05. | ZHAOKE OPHTH-B (06622): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 16, 2025 | - | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 16, 2025 | - | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED RE-ELECTION OF THE RETIRING ... | 1 | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024 | - | HKEx | ||
24.04. | ZHAOKE OPHTH-B (06622): 2024 ANNUAL REPORT | - | HKEx | ||
17.04. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN THE ADDITIONAL PHASE III CLINICAL TRIAL OF CYCLOSPORINE A (CSA) OPHTHALMIC ... | - | HKEx | ||
16.04. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERING INTO THREE DISTRIBUTION AGREEMENTS WITH INTERPHARMA TO COMMERCIALIZE NVK002, BRIMOCHO TM PF ... | 1 | HKEx | ||
11.04. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - UPDATES ON BRIMOCHOL TM PF FOR PRESBYOPIA | 1 | HKEx | ||
01.04. | ZHAOKE OPHTH-B (06622): CONNECTED TRANSACTION ANNOUNCEMENT RENEWAL OF THE LEASE AGREEMENT | 1 | HKEx | ||
24.03. | ZHAOKE OPHTH-B (06622): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION OF WEALTH ... | - | HKEx | ||
07.03. | ZHAOKE OPHTH-B (06622): NOTICE OF BOARD MEETING | - | HKEx | ||
18.02. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 18.02.2025 | 677 | Xetra Newsboard | The following instruments on XETRA do have their first trading 18.02.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.02.2025
Aktien
1 GB00BN0VZ646 Ferrari Group PLC
2... ► Artikel lesen | |
13.01. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERING INTO DISTRIBUTION AGREEMENT WITH AFT PHARMACEUTICALS TO COMMERCIALIZE BRIMOCHOL TM PF IN AUSTRALIA ... | 2 | HKEx | ||
02.01. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF ABBREVIATED NEW DRUG APPLICATION FOR NVK002 FOR TREATMENT OF MYOPIA PROGRESSION IN ... | 3 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Evotec-Aktie: Kurs legt zu (6,734 €) | Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | BioNTech-Aktie: Merkwürdiges Kursverhalten | © Foto: SymbolbildDer steinige Weg vom Corona-Helden zum Krebs-Jäger. So hätte auch die Überschrift lauten können, denn die Mainzer sorgen derzeit für Aufsehen mit Übernahmen und Kooperationen. Einmal... ► Artikel lesen | |
ONCO-INNOVATIONS | 1,380 | +0,73 % | EQS-Media: Onco-Innovations Ltd.: Erhebliche Aufwärtsperspektive für frühe Investoren? Neue Studie unterstützt die Anwendbarkeit der Ergebnisse klinischer Lungenkrebsstudien | EQS-Media / 21.06.2025 / 15:37 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass die Mitbegründer seiner hundertprozentigen... ► Artikel lesen | |
VOR BIOPHARMA | 1,040 | +16,85 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
NUVALENT | 79,66 | +0,53 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target | ||
CITIUS ONCOLOGY | 4,520 | +29,14 % | Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR | WASHINGTON (dpa-AFX) - Citius Oncology, Inc. (CTOR), the oncology-focused subsidiary of late-stage biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR), announced Monday it has entered... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 13,740 | -4,58 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
ARCELLX | 65,30 | +0,79 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ARS PHARMACEUTICALS | 18,215 | +0,75 % | ARS Pharmaceuticals, Inc. - 8-K, Current Report |